How fibroblast growth factor 23 works

Journal of the American Society of Nephrology

Volumn 18, Issue 6, 2007, Pages 1637-1647

  Liu, Shiguang ^a   Quarles, L Darryl ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b MS 3018   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; FIBROBLAST GROWTH FACTOR 23;

BONE DISEASE; BONE MINERALIZATION; HYPEROSTOSIS; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MINERAL METABOLISM; OSTEOMALACIA; PARATHYROID FUNCTION; PHOSPHATE METABOLISM; PRIORITY JOURNAL; REVIEW; RICKETS; SOFT TISSUE CALCIFICATION; VITAMIN D METABOLISM;

EID: 34249883939     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2007010068     Document Type: Review

References (81)

1. Schmidt-Nielsen K: Animal Physiology Adaptation and Environment, Cambridge University Press, New York, 1975
2. Itoh N, Ornitz DM: Evolution of the Fgf and Fgfr gene families. Trends Genet 20: 563-569, 2004
3. Yamashita T, Yoshioka M, Itoh N: Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277: 494-498, 2000
4. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505, 2001
5. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ: Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079-2086, 2001
6. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD: Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426, 2003
7. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-E49, 2006
8. Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J: Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19: 1842-1844, 2005
9. The HYP Consortium: A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11: 130-136, 1995
10. Fisher LW, Fedarko NS: Six genes expressed in bones and teeth encode the current members of the SIBLING family of proteins. Connect Tissue Res 44[Suppl 1]: 33-40, 2003
11. Ornitz DM: FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bioessays 22: 108-112, 2000
12. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006
13. Yu X, Ibrahimi OA, Goetz R, Zhang F, Davis SI, Garringer HJ, Linhardt RJ, Ornitz DM, Mohammadi M, White KE: Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146: 4647-4656, 2005
14. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281: 6120-6123, 2006
15. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997
16. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson KB: Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 145: 3087-3094, 2004
17. Bai X, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology 145: 5269-5279, 2004
18. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE: Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315, 2006
19. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T: Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568, 2004
20. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B: Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004
21. Kato K, Jeanneau C, Tarp MA, Benet-Pages A, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H: Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281: 18370-18377, 2006
22. Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito M, Kuwahata M, Imura A, Nabeshima Y, Miyamoto K: Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 292: F769-F779, 2007
23. Hesse M, Frohlich LF, Zeitz U, Lanske B, Erben RG: Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice. Matrix Biol 26: 75-84, 2007
24. Sitara D, Razzaque MS, St-Arnaud R, Huang W, Taguchi T, Erben RG, Lanske B: Genetic ablation of vitamin d activation pathway reverses biochemical and skeletal anomalies in fgf-23-null animals. Am J Pathol 169: 2161-2170, 2006
25. Stubbs J, Liu S, Tang W, Quarles LD: Role of hyperphosphatemia and 1,25(OH)2D3 in vascular calcifications and mortality in FGF23 null mice [Abstract]. J Am Soc Nephrol 17: 689A, 2006
26. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K: Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 29: 91-99, 2004
27. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B: An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14: 385-390, 2005
28. Larsson T, Davis SI, Garringer HJ, Mooney SD, Draman MS, Cullen MJ, White KE: Fibroblast growth factor-23 mutants causing familial tumoral calcinosis are differentially processed. Endocrinology 146: 3883-3891, 2005
29. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kakitani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T: Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088-F1095, 2005
30. Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, Miyamoto K, Fukushima N: Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate cotransport activity and 1alpha,25-dihydroxyvitamin D3 production. J Biol Chem 278: 2206-2211, 2003
31. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD: Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006
32. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N: Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280: 2543-2549, 2005
33. Lorenz-Depiereux B, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM: DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38: 1248-1250, 2006
34. Liu S, Rowe PS, Vierthaler L, Zhou J, Quarles LD: Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity. J Endocrinol 192: 261-267, 2007
35. Burnett SA, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS: Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res 21: 1187-1196, 2006
36. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
37. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E: Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006
38. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 65: 1943-1946, 2004
39. Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234, 2003
40. Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR: MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34: 303-319, 2004
41. Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G: Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Invest 116: 3150-3159, 2006
42. Bai X, Miao D, Panda D, Grady S, McKee MD, Goltzman D, Karaplis AC: Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 16: 2913-2925, 2002
43. Erben RG, Mayer D, Weber K, Jonsson K, Juppner H, Lanske B: Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res 20: 1149-1160, 2005
44. Liu S, Guo R, Tu Q, Quarles LD: Overexpression of Phex in osteoblasts fails to rescue the Hyp mouse phenotype. J Biol Chem 277: 3686-3697, 2002
45. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284: 977-981, 2001
46. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM: FGF23 is processed by proprotein convertases but not by PHEX. Bone 35: 455-462, 2004
47. Guo R, Liu S, Spurney RF, Quarles LD: Analysis of recombinant Phex: An endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 281: E837-E847, 2001
48. Zhang F, Zhai G, Kato BS, Hart DJ, Hunter D, Spector TD, Ahmadi KR: Association between KLOTHO gene and hand osteoarthritis in a female Caucasian population. Osteoarthritis Cartilage January 29, 2007 [epub ahead of print]
49. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, Quarles LD: Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16: 1645-1653, 2005
50. Li YC, Pirro AE, Amling M, Delling G, Baron R, Bronson R, Demay MB: Targeted ablation of the vitamin D receptor: An animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A 94: 9831-9835, 1997
51. Inoue Y, Segawa H, Kaneko I, Yamanaka S, Kusano K, Kawakami E, Furutani J, Ito M, Kuwahata M, Saito H, Fukushima N, Kato S, Kanayama HO, Miyamoto K: Role of the vitamin D receptor in FGF23 action on phosphate metabolism. Biochem J 390: 325-331, 2005
52. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto K: Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288: E1101-E1109, 2005
53. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA: Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 5358-5364, 2005
54. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE: Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 36: 971-977, 2005
55. Quarles LD: Evidence for a bone-kidney axis regulating phosphate homeostasis. J Clin Invest 112: 642-646, 2003
56. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Ghishan FK: 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: The final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005
57. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA: Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22: 6267-6276, 2003
58. Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, Goto H, Ohashi H, Koyano HM, Mochizuki R, Miki T, Inaba M, Nishizawa Y: Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci 78: 2295-2301, 2006
59. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112: 683-692, 2003
60. Shore EM, Ahn J, Jan de Beur S, Li M, Xu M, Gardner RJ, Zasloff MA, Whyte MP, Levine MA, Kaplan FS: Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 346: 99-106, 2002
61. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R: Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest 112: 785-794, 2003
62. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R: FGF7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90: 1012-1020, 2005
63. Carey DE, Drezner MK, Hamdan JA, Mange M, Ahmad MS, Mubarak S, Nyhan WL: Hypophosphatemic rickets/ osteomalacia in linear sebaceous nevus syndrome: A variant of tumor-induced osteomalacia. J Pediatr 109: 994-1000, 1986
64. Heike CL, Cunningham ML, Steiner RD, Wenkert D, Hornung RL, Gruss JS, Gannon FH, McAlister WH, Mumm S, Whyte MP: Skeletal changes in epidermal nevus syndrome: Does focal bone disease harbor clues concerning pathogenesis? Am J Med Genet A 139: 67-77, 2005
65. Hoffman WH, Jueppner HW, Deyoung BR, O'Dorisio MS, Given KS: Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am J Med Genet A 134: 233-236, 2005
66. Pande S, Ritter CS, Rothstein M, Wiesen K, Vassiliadis J, Kumar R, Schiavi SC, Slatapolsky E, Brown AJ: FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol 104: p23-p32, 2006
67. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
68. Bhan I, Shah A, Holmes J, Isakova T, Gutierrez O, Burnett SA, Juppner H, Wolf M: Post-transplant hypophosphatemia: Tertiary 'hyper-phosphatoninism'? Kidney Int 70: 1486-1494, 2006
69. Evenepoel P, Naesens M, Claes K, Kuypers D, Vanrenterghem Y: Tertiary 'hyperphosphatoninism' accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant March 19, 2007 [epub ahead of print]
70. Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T: A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 90: 5523-5527, 2005
71. Campagnoli MF, Pucci A, Garelli E, Carando A, Defilippi C, Lala R, Ingrosso G, Dianzani I, Forni M, Ramenghi U: Familial tumoral calcinosis and testicular microlithiasis associated with a new mutation of GALNT3 in a white family. J Clin Pathol 59: 440-442, 2006
72. Garringer HJ, Fisher C, Larsson TE, Davis SI, Koller DL, Cullen MJ, Draman MS, Conlon N, Jain A, Fedarko NS, Dasgupta B, White KE: The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N- acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. J Clin Endocrinol Metab 91: 4037-4042, 2006
73. Ichikawa S, Imel EA, Sorenson AH, Severe R, Knudson P, Harris GJ, Shaker JL, Econs MJ: Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab 91: 4472-4475, 2006
74. Specktor P, Cooper JG, Indelman M, Sprecher E: Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred. J Hum Genet 51: 487-490, 2006
75. Hamada J, Tamai K, Ono W, Saotome K: Uremic tumoral calcinosis in hemodialysis patients: Clinicopathological findings and identification of calcific deposits. J Rheumatol 33: 119-126, 2006
76. Quarles LD, Murphy G, Econs MJ, Martinez S, Lobaugh B, Lyles KW: Uremic tumoral calcinosis: Preliminary observations suggesting an association with aberrant vitamin D homeostasis. Am J Kidney Dis 18: 706-710, 1991
77. Sabeel A, Al-Homrany M: Complete resorption of massive soft tissue calcification in a hemodialysis patient after parathyroidectomy. Am J Nephrol 20: 421-424, 2000
78. Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ: Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91: 2055-2061, 2006
79. Makitie O, Kooh SW, Sochett E: Prolonged high-dose phosphate treatment: A risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets. Clin Endocrinol (Oxf) 58: 163-168, 2003
80. Verge CF, Lam A, Simpson JM, Cowell CT, Howard NJ, Silink M: Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 325: 1843-1848, 1991
81. Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD, Alon US: FGF-23 and 1,25D in children with hypophosphatemic rickets: Effect of treatment with phosphate. J Bone Miner Res 21: S318, 2006